 Uliledlimab is a highly differentiated CD73 antibody with a unique epitope that confers pharmacological advantages Data from U.S. phase 1 dose escalation trial demonstrates favorable safety and tolerability with no dose-limiting toxicities; preliminary clinical activity of uliledlimab has been observed in patients with advanced cancers ASCO abstract among Top 12 selected for poster discussion I-Mab to host call for investors on June 7, 2021 at 8 am ET SHANGHAI and GAITHERSBURG, Md., May 19, 2021 PRNewswire -- I-Mab the Company Nasdaq: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that an abstract detailing clinical data from its U.S. phase 1 study of uliledlimab in combination with atezolizumab TECENTRIQ in patients with advanced cancer will be presented at the 2021 American Society of Clinical Oncology ASCO Annual Meeting, taking place June 4-8, 2021. 